Abstract. Accumulating evidence indicates a pivotal role for neuroinflammation in ischemic and excitotoxic brain injury. Cytokine-induced neutrophil chemoattractant-1 (CINC-1) is a CXC chemokine implicated in the infiltration of inflammatory cells into the brain parenchyma. In this study, we investigated the effect of N-methyl-D-aspartate (NMDA)-induced neuronal injury on CINC-1 production in the organotypic cortico-striatal slice cultures. Treatment with 50 μM NMDA for 3 -4 h caused devastating neuronal damage and increased CINC-1 production. Immunohistochemical analysis revealed that the CINC-1 immunoreactivity was predominantly detected in astrocytes. NMDA failed to induce CINC-1 production in enriched astrocyte cultures or neuron-depleted slice cultures, suggesting that NMDA acted on neuronal cells to induce astrocytic CINC-1 production. NMDA-induced CINC-1 mRNA expression was significantly inhibited by U0126, a mitogen-activated protein kinase / extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor. These results suggest that NMDA-evoked neuronal injury induced astrocytic CINC-1 production via a MEK / ERK signaling pathway. Manipulation of this signaling pathway may serve as a target for suppressing neuroinflammation and, thereby, treating ischemic brain injury.
Introduction
Accumulating evidence indicates a pivotal role for neuroinflammation in ischemic and excitotoxic brain injury (1, 2) . It has been reported that the levels of proinflammatory cytokines such as tumor necrosis factor-α and interleukin-1β, chemokines such as monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1α are markedly increased in the brain after middle cerebral artery occlusion (3 -6) . Cytokine-induced neutrophil chemoattractant-1 (CINC-1), a member of the CXC chemokine family, is also upregulated in the ischemic brain (5, 7, 8) . Under ischemic conditions, leukocytes infiltrate into the brain parenchyma from the circulation. CC chemokines such as MCP-1 are involved in the infiltration of monocytelineage leukocytes, while CXC chemokines such as CINC-1 play an important role in neutrophil infiltration. However, the underlying mechanisms for up-regulation of chemokine production in the brain under pathological conditions are poorly understood. Mitogen-activated protein kinases (MAPKs) are a family of serine / threonine kinases that are activated in response to various extracellular stimuli and mediate signal transduction from the cell surface to the nucleus. Therefore, in this study, we examined the involvement of MAPKs in neuronal injury-induced CINC-1 production in organotypic cortico-striatal slice cultures. Our results demonstrate that activation of the extracellular signal-regulated kinase (ERK) signaling pathway plays a key role in neuronal injury-induced CINC-1 production in astrocytes.
Materials and Methods

Materials
N-Methyl-D-aspartate (NMDA) was purchased from Nacalai Tesque (Kyoto). The NMDA-receptor antagonist MK-801 and the MAPK / ERK kinase (MEK) inhibitor U0126 were purchased from Sigma (St. Louis, MO, USA). The c-Jun N-terminal kinase (JNK) inhibitor SP600125 was from Biomol (Plymouth, PA, USA), and the p38 MAPK inhibitor SB203580 was from Calbiochem (San Diego, CA, USA). All other drugs and chemicals, unless otherwise noted, were purchased from Nacalai Tesque.
Cell cultures
All experiments using animals were approved by the Institutional Animal Experimentation Committee of Hokkaido University. Organotypic cortico-striatal slice cultures were prepared as described previously (9, 10) . Briefly, postnatal 2 -3-day-old Wistar rats (Japan SLC, Hamamatsu) were decapitated under aseptic conditions, and their brains were rapidly removed and separated into two hemispheres. Coronal slices (300-μm-thick) containing the cerebral cortex and striatum were prepared using a tissue chopper (Narishige, Tokyo) and transferred onto 30-mm Millicell-CM insert membranes (pore size of 0.4 μm; Millipore, Bedford, MA, USA) placed in 6-well culture plates, with 700 μL of culture medium per well. Four slices were cultivated on each membrane at the interface between the air and culture medium. The culture medium consisted of 50% HEPESbuffered minimum essential medium (MEM; Invitrogen, Carlsbad, CA, USA), 25% Hanks' balanced salt solution (Invitrogen), and 25% heat-inactivated horse serum (Invitrogen), supplemented with 6.5 mg / mL D-glucose, 2 mM L-glutamine, 100 U / mL penicillin G sodium, and 100 µg/mL streptomycin sulfate. Slices were maintained at 37°C in a humidified incubator with 5% CO 2 / 95% air for 10 -11 days before use.
Primary enriched astrocyte cultures were prepared from postnatal 1-day-old rats as previously described (11) . Briefly, cerebral cortices were stripped of the meninges, digested with dispase (Invitrogen), and then filtered through 40-μm pore nylon mesh. Dissociated cells were plated onto 75-cm 2 tissue culture flasks with 7 mL of Eagle's MEM (Nissui Pharmaceutical, Tokyo), supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 23.8 mM NaHCO 3 . After cultivation for 10 -14 days at 37°C in a humidified incubator with 5% CO 2 / 95% air, the flasks were shaken on an orbital shaker at 250 rpm for 17 h to remove microglia, oligodendrocytes, and oligodendrocyte / type II astrocyte progenitor cells. After 12 -14 days of culture in 24-well culture plates containing 500 μL culture medium per well, astrocytes at confluence were used in experiments. The purity of astrocytes was >95%, as determined by immunostaining for the astrocytic marker glial fibrillary acidic protein (GFAP).
Drug treatment and sample preparation
To investigate the time course of CINC-1 release after NMDA treatment, cultured slices or enriched astrocytes were treated with 50 μM NMDA for 4 h. Culture media were collected at 4 (just after the end of NMDA treatment), 8, 12, 28 , and 76 h after the start of NMDA treatment to determine the concentration of CINC-1 by ELISA. To examine the effect of NMDA on CINC-1 mRNA expression, cultured slices were collected at 0 (pre), 1, 3, 6, 9, and 27 h after the beginning of NMDA treatment for RNA extraction. To examine the effect of MK-801 on NMDA (50 μM, 3 h)-induced CINC-1 production, MK-801 at a concentration of 1 μM was included in the culture medium from 3 h before the beginning of NMDA treatment to the end of NMDA treatment. In the experiments to investigate the effects of MAPK inhibitors, the inhibitors were included in the culture medium from 3 h before the beginning of NMDA treatment to the end of post-incubation. In the experiments using neuron-depleted slice cultures, the slices were pretreated with 100 μM NMDA for 3 h at 10 days in vitro (DIV) to eliminate neuronal cells. At 13 DIV, these slices were treated with 50 μM NMDA for 3 h, followed by 24 h of post-incubation before collecting the media for ELISA. For double immunostaining, the slices were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) containing 4% sucrose for 2 h at 4°C and stored in 25% sucrose containing 0.05% sodium azide at 4°C until use.
Real-time RT-PCR
Total RNA was extracted using ISOGEN (Nippon Gene, Tokyo) following the manufacturer's protocol. RNA was treated with deoxyribonuclease (Nippon Gene) to degrade any contaminating genomic DNA and reverse-transcribed to first-strand cDNA using the ExScript RT reagent Kit (Takara Bio, Otsu). Quantitative real-time RT-PCR using SYER Premix Ex Taq (Takara Bio) was performed on the ABI PRISM 7700 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), with the following conditions: 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous reference gene to normalize the expression level of CINC-1. The following sequencespecific primers were used: CINC-1 forward, 5'-GGTAGGCGTTAAATATCTCG-3'; CINC-1 reverse, 5'-ACATTCCTCACCCTAACACA-3'; GAPDH forward, 5'-GGGCTGCCTTCTCTTGTGAC-3'; GAPDH reverse, 5'-TTGAACTTGCCGTGGGTAGA-3'.
The relative quantification of mRNA levels was performed using the comparative threshold cycle method (2 −ΔΔCt method) (12) .
Immunohistochemistry
Fixed slices were rinsed with PBS, incubated in blocking solution (1.5% normal donkey serum and 0.3% Triton X-100 in PBS) for 1 h, and then incubated with goat anti-rat CINC-1 antibody (2 μg / mL; R&D Systems, Minneapolis, MN, USA) and each of the mouse antibodies against the cell marker proteins for astrocytes, microglia, or neurons as follows: anti-GFAP antibody for astrocytes (1:500, Sigma), anti-OX42 antibody for microglia (3.3 μg/ mL; Serotec, Oxford, UK), and anti-NeuN antibody for neurons (3.3 µg/mL; Chemicon International, Temecula, CA, USA). After incubation with the primary antibodies in blocking solution overnight at 4°C, the slices were rinsed in PBS and then incubated with secondary antibodies for 1 h. For the secondary antibodies, Alexa Fluor 488-labeled donkey anti-goat IgG antibody and Alexa Fluor 568-labeled donkey anti-mouse IgG antibody (5 μg/ mL each, Invitrogen) were used. After rinsing in PBS, the slices were mounted on glass slides and coverslipped with VectaShield (Vector Laboratories, Burlingame, CA, USA). Immunofluorescence was visualized on a Zeiss Axioplan 2 fluorescence microscope equipped with a laser scanning confocal imaging system (LSM510; Carl Zeiss, Jana, Germany).
ELISA
The concentration of CINC-1 in the culture medium was determined by using an ELISA kit (IBL Co., Ltd., Takasaki), according to the manufacturer's instructions. The detection limit of the ELISA kit was 4.7 pg / mL.
Statistical analyses
Data are presented as the mean ± S.E.M. The time course of CINC-1 mRNA expression and the effects of MAPK inhibitors on CINC-1 mRNA expression were compared by a one-way analysis of variance (ANOVA), followed by Student-Newman-Keuls' post hoc multiple comparison test. Two-way ANOVA followed by Bonferroni' post hoc multiple comparison test was used for the time course study of CINC-1 protein release. For the experiments with MK-801 and the experiments using neuron-depleted slice cultures, the data were analyzed by the Mann-Whitney U-test. Differences with P<0.05 were considered statistically significant.
Results
NMDA induces astrocytic CINC-1 production in the slice cultures
The treatment with 50 µM NMDA for 3 h dramatically injured neuronal cells in the organotypic cortico-striatal slice cultures, as previously reported (13) . ELISA revealed that NMDA treatment markedly promoted the release of CINC-1 in the slice cultures. The concentrations of CINC-1 in the media were significantly higher in the NMDA-treated cultures than in the vehicle-treated ones at 28 and 76 h (Fig. 1A) . To examine whether the increased CINC-1 was due to the up-regulated synthesis of this protein or the release / leakage of stored protein, the level of CINC-1 mRNA was examined by real-time RT-PCR. Figure 1B shows that NMDA treatment significantly elevated the level of CINC-1 mRNA at 6, 9, and 27 h, suggesting the up-regulation of de novo synthesis of CINC-1 protein. NMDA-induced CINC-1 production was significantly (P<0.05) blocked by coadministration of MK-801, a NMDA-receptor antagonist. CINC-1 concentrations in the media at 27 h were 6.5 ± 2.8 (n = 4) and 125.2 ± 36.0 (n = 4) pg / mL in the cultures treated with NMDA in the presence or absence of MK-801, respectively. Double immunostaining demonstrated that CINC-1 immunoreactivity was predominantly detected in GFAP-immunopositive astrocytes ( Fig. 2: A, B) , but not OX-42-positive microglia (Fig. 2C) or NeuN-positive neurons (Fig. 2D ).
NMDA acts on neuronal cells to induce astrocytic CINC-1 production
In astrocyte-enriched cultures, NMDA did not increase the levels of CINC-1 in the media, compared with the vehicle-treated group (Fig. 3A) . Next, we examined the effect of NMDA on CINC-1 production in neurondepleted slice cultures. Immunostaining showed that most of the NeuN-positive cells were eliminated from the cultured slices at 13 DIV by pretreatment with NMDA (100 μM, 3 h) at 10 DIV. Pretreatment with the high concentrations of NMDA induced CINC-1 production, but this induction subsided 24 h after the pretreatment (data not shown). Thus, we used the NMDApretreated slices as the neuron-depleted ones at 13 DIV. In the neuron-depleted slices, treatment with NMDA (50 μM) did not induce CINC-1 production, while NMDA increased the level of CINC-1 in the control slices (vehicle-pretreated slices) (Fig. 3B) . 
Effects of MAPK inhibitors on NMDA-induced CINC-1 mRNA expression
The involvement of MAPKs in NMDA-induced CINC-1 production was examined using specific inhibitors for the MAPK pathway (Fig. 4) . CINC-1 mRNA expression 6 h after NMDA treatment was significantly suppressed by the MEK inhibitor U0126. On the other hand, SP600125, a JNK inhibitor, and SB203580, a p38 MAPK inhibitor, did not affect CINC-1 mRNA expression. None of these inhibitors significantly affected NMDA-induced neuronal injury (data not shown).
Discussion
In the present study, we demonstrated that NMDA induced astrocytic CINC-1 production in organotypic cortico-striatal slice cultures. NMDA failed to induce CINC-1 production in enriched astrocyte cultures or neuron-depleted slice cultures, indicating that NMDA acts on neuronal cells to induce astrocytic CINC-1 production. It has been reported that CINC-1 production is up-regulated by acidosis, oxidative stress, and activation of protease-activated receptors in enriched astrocyte cultures (14 -16) . In addition, intracerebroventricular administration of an endothelin ET B -receptor agonist enhanced the level of CINC-1 in the striatum and cerebrum (17) . Because these stimuli inducing CINC-1 production are implicated in ischemic / excitotoxic neuronal injury, NMDA-induced astrocytic CINC-1 production observed in this study is likely to be due to NMDA-evoked neuronal injury. Although the mediators connecting neuronal injury to astrocytic CINC-1 production remain unclear, adenosine 5'-triphosphate (ATP), which is known to be released / leaked from injured cells (18, 19) , is one of the candidates of such mediators. Indeed, our preliminary experiments showed that ATP increased CINC-1 mRNA expression in enriched astrocyte cultures and that adenosine 5'-O-(3-thiotriphosphate), a hydrolysis-resistant ATP analog, induced CINC-1 protein production in cortico-striatal slice cultures (T. Katayama et al., unpublished data). Further studies are needed to determine the mediators released from injured neurons.
We showed that NMDA-induced CINC-1 production was significantly inhibited by a MEK inhibitor U0126, suggesting the involvement of MEK / ERK signaling. It has been reported that astrocytic MCP-1 production induced by purinergic receptor activation is also mediated by a MEK/ ERK pathway (20) . Furthermore, in preliminary experiments, we found that MEK / ERK signaling was involved in NMDA-induced MCP-1 up-regulation in cortico-striatal slice cultures (21) . Pathological roles of these chemokines in the brain have been investigated. Systemic administration of neutralizing antibody against CINC-1 ameliorated brain edema following ischemic reperfusion injury in rats (22) , and interleukin-1β-induced blood-brain barrier breakdown in juvenile rats was attenuated by intra-striatal injection of CINC-1-neutralizing antibody (23) . In addition, deletion of the MCP-1 gene by homologous recombination afforded brain protection against focal cerebral ischemia (24), while overexpression of MCP-1 under control of the myelin basic protein promoter exacerbated ischemic brain injury (25) . These findings suggest that these chemokines play a crucial role in ischemic brain injury and that inhibition of production of these proteins may attenuate ischemic brain injury. In this study, we added a CXC chemokine, CINC-1, to the list of chemokines, the synthesis of which is positively regulated via a MEK/ ERK cascade. Manipulation of this signaling pathway may serve as a target for treating ischemic brain injury. Fig. 4 . Effects of MAPK inhibitors on NMDA-induced CINC-1 mRNA expression. The MEK inhibitor U0126, the JNK inhibitor SP600125, or the p38 MAPK inhibitor SB203580 (30 μM each) was included in the culture medium from 3 h before the beginning of NMDA treatment to the end of post-incubation. Total RNA was extracted from the cultured slices 3 h after the end of NMDA treatment, and relative changes in mRNA levels were determined by quantitative real-time RT-PCR. Values are given in arbitrary units and expressed as fold change over the NMDA alone-treated group. Data are each presented as the mean ± S.E.M. from three independent experiments. U, U0126; SP, SP600125; SB, SB203580. # P<0.05 vs vehicle-treated group; *P<0.05 vs NMDA alone-treated group.
